Navitoclax and ruxolitinib for patients with myelofibrosis and JAK inhibitor experience: response duration in phase 2 study

According to phase 2 multicenter data presented during the 2021 European Hematology Association Virtual Congress, 44% of patients with myelofibrosis that is unresponsive to ruxolitinib monotherapy who were treated with ruxolitinib plus navitoclax—a small-molecule inhibitor of antiapoptotic B-cell lymphoma 2 proteins—experienced spleen volume reduction of ≥35% during the study (27% by Week 24). Further, 41% achieved a ≥50% reduction in total symptom score during the study (30% by Week 24).